These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 25944695

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas.
    Mehra S, Nicholls M, Taylor J.
    Int J Mol Sci; 2024 Jul 09; 25(14):. PubMed ID: 39062757
    [Abstract] [Full Text] [Related]

  • 23. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, Bocchia M.
    Anticancer Agents Med Chem; 2017 Jul 09; 17(8):1040-1045. PubMed ID: 27697038
    [Abstract] [Full Text] [Related]

  • 24. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y, Li J, Ding N, Wang X, Deng L, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Song Y, Zhu J.
    J Exp Clin Cancer Res; 2019 Feb 18; 38(1):86. PubMed ID: 30777096
    [Abstract] [Full Text] [Related]

  • 25. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
    Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V.
    Clin Cancer Res; 2017 Jul 15; 23(14):3734-3743. PubMed ID: 28034907
    [Abstract] [Full Text] [Related]

  • 26. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z, Zhang D, Liu Y, Yang D, Ran F, Wang ML, Zhao G.
    Arch Pharm (Weinheim); 2018 Jul 15; 351(7):e1700369. PubMed ID: 29741794
    [Abstract] [Full Text] [Related]

  • 27. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q, Wang HY, Liu X, Nunez-Cruz S, Jillab M, Melnikov O, Nath K, Glickson J, Wasik MA.
    J Immunol; 2019 Oct 15; 203(8):2043-2048. PubMed ID: 31534006
    [Abstract] [Full Text] [Related]

  • 28. Ibrutinib and novel BTK inhibitors in clinical development.
    Akinleye A, Chen Y, Mukhi N, Song Y, Liu D.
    J Hematol Oncol; 2013 Aug 19; 6():59. PubMed ID: 23958373
    [Abstract] [Full Text] [Related]

  • 29. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
    Balsas P, Esteve-Arenys A, Roldán J, Jiménez L, Rodríguez V, Valero JG, Chamorro-Jorganes A, de la Bellacasa RP, Teixidó J, Matas-Céspedes A, Moros A, Martínez A, Campo E, Sáez-Borderías A, Borrell JI, Pérez-Galán P, Colomer D, Roué G.
    J Hematol Oncol; 2017 Mar 31; 10(1):80. PubMed ID: 28359287
    [Abstract] [Full Text] [Related]

  • 30. New roles for B cell receptor associated kinases: when the B cell is not the target.
    Nguyen PH, Niesen E, Hallek M.
    Leukemia; 2019 Mar 31; 33(3):576-587. PubMed ID: 30700840
    [Abstract] [Full Text] [Related]

  • 31. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies.
    Alfaro J, Pérez de Arce F, Belmar S, Fuentealba G, Avila P, Ureta G, Flores C, Acuña C, Delgado L, Gaete D, Pujala B, Barde A, Nayak AK, Upendra TVR, Patel D, Chauhan S, Sharma VK, Kanno S, Almirez RG, Hung DT, Chakravarty S, Rai R, Bernales S, Quinn KP, Pham SM, McCullagh E.
    J Pharmacol Exp Ther; 2017 May 31; 361(2):312-321. PubMed ID: 28298527
    [Abstract] [Full Text] [Related]

  • 32. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
    Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, Stathis A, Goodstal S, Zucca E, Bertoni F.
    Ann Oncol; 2016 Jun 31; 27(6):1123-1128. PubMed ID: 26961147
    [Abstract] [Full Text] [Related]

  • 33. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
    Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, McClanahan F, Harrington BK, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner A, Woyach JA.
    Clin Cancer Res; 2017 Jun 01; 23(11):2831-2841. PubMed ID: 27903679
    [Abstract] [Full Text] [Related]

  • 34. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
    Ran F, Liu Y, Chen X, Zhuo H, Xu C, Li Y, Duan X, Zhao G.
    Bioorg Chem; 2021 Jul 01; 112():104968. PubMed ID: 34000704
    [Abstract] [Full Text] [Related]

  • 35. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
    Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ.
    Cell Signal; 2013 Jan 01; 25(1):106-12. PubMed ID: 22975686
    [Abstract] [Full Text] [Related]

  • 36. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
    Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL.
    Leukemia; 2014 Mar 01; 28(3):649-57. PubMed ID: 24270740
    [Abstract] [Full Text] [Related]

  • 37. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
    Battistello E, Katanayeva N, Dheilly E, Tavernari D, Donaldson MC, Bonsignore L, Thome M, Christie AL, Murakami MA, Michielin O, Ciriello G, Zoete V, Oricchio E.
    Blood; 2018 May 24; 131(21):2345-2356. PubMed ID: 29567799
    [Abstract] [Full Text] [Related]

  • 38. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C, Niemann CU.
    Drugs; 2018 Nov 24; 78(16):1653-1663. PubMed ID: 30390220
    [Abstract] [Full Text] [Related]

  • 39. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.
    Clin Cancer Res; 2016 Jun 01; 22(11):2684-96. PubMed ID: 26819453
    [Abstract] [Full Text] [Related]

  • 40. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ, Song PR, Dou D, Diao YY, Tong LJ, Zhang T, Xie H, Li HL, Ding J.
    Acta Pharmacol Sin; 2020 Mar 01; 41(3):415-422. PubMed ID: 31316181
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.